Video

Urology Times 50 Innovations Series: Dr. Kelvin Moses on sipuleucel-T for mCRPC

Author(s):

Urology Times staff

“In using an immune therapy approach, and using your own cells, it's very innovative in the mechanism that it works,” says Kelvin A. Moses, MD, PhD.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Urology Times® is celebrating its 50th anniversary in 2022. To mark the occasion, we are high-lighting 50 of the top innovations and developments that have transformed the field of urology over the past 50 years. In this installment, Kelvin A. Moses, MD, PhD, discusses the prostate cancer treatment sipuleucel-T (Provenge). Moses is an associate professor of urology and fellowship director of urologic oncology at Vanderbilt University Medical Center, Nashville, Tennessee.

      Related Videos
      Prostate cancer screening: Expert weighs in after Biden's diagnosis
      Prostate cancer screening: Expert weighs in after Biden's diagnosis
      1 expert in this video
      Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT
      1 expert in this video
      Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses
      Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
      Study results affirm effectiveness of evolving prostate cancer therapies
      Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
      Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
      Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
      Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
      Rebecca A. Campbell, MD, answers a question during a Zoom video interview
      Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
      1 expert in this video
      Comparing Trials Studying Treatment Intensification In mHSPC
      An Overview of the ARANOTE Trial
      An Overview of the ARANOTE Trial
      Nitin Yerram, MD, on a liquid biopsy urine test for prostate cancer
      Nitin Yerram, MD, on a liquid biopsy urine test for prostate cancer
      Related Content
      Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer
      May 20th 2025

      Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer

      Hannah Clarke
      Results from the phase 3 AMPLIFY trial are intended to support an application to the FDA for potential approval of 64Cu-SAR-bisPSMA.
      Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause
      April 28th 2025

      Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause

      Melissa Kaufman, MD, PhD, FACS
      In this episode, guideline chair Melissa Kaufman, MD, PhD, FACS, highlights key points from the new AUA GSM guideline and illustrates its impact for clinical management of this condition.
      Study shows value of precision-based approaches in prostate cancer
      May 19th 2025

      Study shows value of precision-based approaches in prostate cancer

      Hannah Clarke
      The study found differences in genomic alteration frequencies between non-Hispanic Black and non-Hispanic White veterans with metastatic prostate cancer, but showed similar survival outcomes.
      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
      April 27th 2025

      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

      Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
      Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
      Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI
      May 16th 2025

      Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI

      Melissa Kaufman, MD, PhD, FACS Hannah Clarke
      The CELLEBRATE trial is aiming to provide additional evidence to support the safety and efficacy of iltamiocel.
      Woman talking with a doctor online using digital tablet | Image Credit: © rh2010 - stock.adobe.com
      May 15th 2025

      Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

      Tracey L. Krupski, MD Jeunice Owens-Walton, MD
      "The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.
      © 2025 MJH Life Sciences

      All rights reserved.